Pharmafile Logo
Pharmafocus logo
Advanced Search

Manufacturing and Production

Showing 15 posts of 5866 posts found.

teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
Appointment
flag_of_the_united_arab_emirates

UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020

October 10, 2016 Manufacturing and Production Abu Dhabi, Dubai, GlobalData, United Arab Emires, growth, medical tourism, pharmaceutical market

United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from …
News
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Feature

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
News
roche_side_building

Roche’s Alecensa receives second FDA Breakthrough Therapy Designation

October 4, 2016 Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib

Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
News
astrazeneca_sign_sky

AstraZeneca’s wins major drug approval by NICE

October 4, 2016 Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
Feature
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016 Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
News

Meet SHL at 2016 PDA Universe of Pre-filled Syringes & Injection Devices

October 3, 2016 Manufacturing and Production

At this year’s PDA Universe of Pre-filled Syringes & Injection Devices, SHL will be showcasing both new technologies and time-tested …
News
Press release
david_goldstein

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …
Appointment
oncology_no_border

Pharmafocus: Advances in Oncology available now!

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, oncology, pharmafocus supplement

The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …
News
The Gateway to Local Adoption Series

Latest content

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026

Scotland starts newborn screening for SMA

March 26, 2026

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026